Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis

Wiener Medizinische Wochenschrift

Volumn 160, Issue 9-10, 2010, Pages 220-224

  Haberhauer, Guenther ^a,b   Strehblow, Christoph ^a   Fasching, Peter ^a  

^a WILHELMINEN HOSPITAL   (Austria)

^b DANUBE UNIVERSITY KREMS   (Austria)

Author keywords

Ankylosing spondylitis; Anti TNF switching; Anti TNF therapy; Arthritis; Psoriatic; Reumatoid arthritis

Indexed keywords

TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SURVIVAL;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; DRUG SUBSTITUTION; DRUG TOLERANCE; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 77955639108     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-010-0795-0     Document Type: Article

References (22)

1. RF van Vollenhoven 2004 Switching between biological agents Clin Exp Rheumatol 22 Suppl 1 S115 S121 1:STN:280:DC%2BD2crns1aiug%3D%3D 15552524
2. JJ Gomez-Reino L Carmona 2006 Switching TNFα antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period Arthritis Res Ther 8 R29 10.1186/ar1881 16507128
3. L Carmona A Ortiz MA Abad 2007 How good is to switch between biologics? A systematic review of the literature Acta Reumatol Port 32 113 128 17572650
4. G Haberhauer P Fasching 2009 Biologika - Verordnungsmodalitäten und "Switching" in der Rheumatologie Klinik 1 59 61
5. G Haberhauer J Feyertag P Fasching 2009 TNF-α-Blockertherapie in der Rheumatologie - Effektivität des Substanzwechsels bei Therapieversagen und bei Nebenwirkungen Universum Inn Med 5 83 85
6. C Delaunay V Farrenq A Marini-Portugal, et al. 2005 Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data J Rheumatol 32 2183 2185 1:CAS:528: DC%2BD2MXht12ltbvF 16265699
7. L Carmona JJ Gomez-Reino 2006 Survival of TNFα antagonists in spondyloarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER Arthr Res Ther 8 R72 10.1186/ar1941
8. F Conti F Ceccarelli E Marocchi, et al. 2007 Switching tumor necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period Ann Rheum Dis 66 1393 1397 10.1136/ard.2007.073569 1:CAS:528:DC%2BD2sXht1Wnu73M 17613555 (Pubitemid 47492489)
9. T Pham B Fautrel E Dernis, et al. 2007 Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update Joint Bone Spine 74 638 646 10.1016/j.jbspin.2007.10.003 1:CAS:528:DC%2BD1cXitlGrsrw%3D 18065252 (Pubitemid 50009179)
10. LC Coates LS Cawkwell NW Ng, et al. 2008 Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience Ann Rheum Dis 67 717 719 10.1136/ard.2007.082925 1:STN:280: DC%2BD1c3ksVGiuw%3D%3D 18055476 (Pubitemid 351571940)
11. DJ Pradeep AC Keat K Gaffney, et al. 2008 Switching anti-TNFα therapy in ankylosing spondylitis Rheumatology (Oxford) 47 1726 1727 10.1093/rheumatology/ken334 1:STN:280:DC%2BD1cnmsVOnuw%3D%3D
12. MC Wick S Lindblad J Bratt, et al. 2005 Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry of Karolinsk University Hospital Scand J Rheumatol 34 353 358 10.1080/ 03009740510026887 1:CAS:528:DC%2BD2MXht1GhtLzF 16234182 (Pubitemid 41545907)
13. G Cohen N Courvoisier JD Cohen, et al. 2005 The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis Clin Exp Rheum 23 795 800 1:STN:280:DC%2BD28%2FhsFCgtQ%3D%3D
14. E Solau-Gervais N Laxenaire B Cortet, et al. 2006 Lack of efficacy of a third tumor necrosis factor α antagonist after failure of a soluble receptor and a monoclonal antibody Rheumatology 45 1121 1124 10.1093/rheumatology/kel054 1:CAS:528:DC%2BD28XhtVWlt7fJ 16510526 (Pubitemid 44542100)
15. SN Nikas PV Voulgari Y Alamanos, et al. 2006 Efficacy and safety of switching from infliximab to adalimumab: a comparison controlled study Ann Rheum Dis 65 257 260 10.1136/ard.2005.039099 1:CAS:528:DC%2BD28XhsFeitb8%3D 15975964 (Pubitemid 43132005)
16. KL Hyrich M Lunt KD Watson, et al. 2007 Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study Arthritis Rheum 56 13 20 10.1002/art.22331 1:CAS:528:DC%2BD2sXhsFaisrw%3D 17195186 (Pubitemid 46106174)
17. E Hjardem M Ostergaard J Podenphant, et al. 2007 Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 66 1185 1189 10.1136/ard.2006.054742 (Pubitemid 47309735)
18. F Iannone F Trotta C Montecucco, et al. 2007 Etanercept maintaines the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects Ann Rheum Dis 66 249 252 10.1136/ard.2006.058776 1:CAS:528:DC%2BD2sXislChsbw%3D 16837489 (Pubitemid 46226063)
19. DE Furst N Gaylis V Bray, et al. 2007 Open-label pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study Ann Rheum Dis 66 893 899 10.1136/ard.2006.068304 1:CAS:528:DC%2BD2sXotlSitL4%3D 17412737 (Pubitemid 46999789)
20. KL Hyrich M Lunt WG Dixon, et al. 2008 Effects of switching between anti-TNFα therapies on HAQ response in patients who do not respond to their first anti-TNFα drug Rheumatology (Oxford) 47 1000 1005 10.1093/rheumatology/ken127 1:CAS:528:DC%2BD1cXnsF2ksL4%3D (Pubitemid 351865923)
21. A Finckh A Ciurea L Brulhart, et al. 2007 B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor α agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor α agents Arthr Rheum 56 1417 1423 10.1002/art.22520 (Pubitemid 46764068)
22. JR Lutt A Deodhar 2008 Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFα antagonists Drugs 68 591 606 10.2165/00003495-200868050-00003 1:CAS:528:DC%2BD1cXmsV2ntbs%3D 18370440 (Pubitemid 351451539)